Good-Heart6425
Explorer
The next round of Demystifying Medicine presentations turns to GLP-1: from its discovery in the lab to a blockbuster therapy for obesity, diabetes and possibly other conditions besides.
Speaking will be Svetlana Mojsov, Ph.D. (Rockefeller) and Yaron Rotman, M.D. (NIH/NIDDK). Running TODAY , remote-only, watchable while the event is on via https://videocast.nih.gov <https://videocast.nih.gov/> and archived afterwards.
**
The session follows the remarkable scientific arc of GLP-1: the early work on gut peptides and glucagon biology, the pinning down of the biologically active GLP-1(7-37) sequence as a 31–amino acid incretin with therapeutic promise, and on to the modern generation of GLP-1 receptor agonists as transformative treatments. We start with the foundational work that defined active GLP-1 and established its insulin-stimulating properties, setting those discoveries inside the wider picture of incretin biology. From there the talk turns to the urgent need for effective therapies in metabolic dysfunction–associated steatohepatitis (MASH), the rationale for GLP-1 receptor agonists in that disease, the key benefits and concerns seen in clinical use, and the NIH studies now under way to pin down mechanisms of action and predictors of response.
Between them, the speakers hope the audience comes away with a clear picture of how fundamental peptide biochemistry produced one of the most consequential therapeutic classes in modern medicine - and which mechanistic and clinical questions are still open.
Svetlana Mojsov <https://www.rockefeller.edu/our-scientists/research-affiliates/1055-svetlana-mojsov/> holds the Lulu Chow Wang and Robin Chemers Neustein Research Associate Professorship at The Rockefeller University. With a Breakthrough Prize in Life Sciences (2025) and a Lasker-DeBakey Clinical Medical Research Award (2024) to her name, Mojsov was central to identifying the biologically active form of GLP-1, GLP-1(7-37), and to showing that it works as an incretin able to stimulate insulin secretion. That work laid critical groundwork for GLP-1-based therapies for type 2 diabetes and obesity.
Yaron Rotman <https://irp.nih.gov/pi/yaron-rotman> is an NIH senior investigator, chief of the Liver & Energy Metabolism Section in the NIDDK Liver Diseases Branch, and an attending hepatologist at the NIH Clinical Center. Mechanistic and translational studies of metabolic dysfunction–associated steatotic liver disease are his focus, drawing on clinical trials, human genetics and experimental models to map the pathways behind hepatic fat accumulation and injury.
With a line-up like that, expect to be dazzled and demystified as always
Speaking will be Svetlana Mojsov, Ph.D. (Rockefeller) and Yaron Rotman, M.D. (NIH/NIDDK). Running TODAY , remote-only, watchable while the event is on via https://videocast.nih.gov <https://videocast.nih.gov/> and archived afterwards.
**
The session follows the remarkable scientific arc of GLP-1: the early work on gut peptides and glucagon biology, the pinning down of the biologically active GLP-1(7-37) sequence as a 31–amino acid incretin with therapeutic promise, and on to the modern generation of GLP-1 receptor agonists as transformative treatments. We start with the foundational work that defined active GLP-1 and established its insulin-stimulating properties, setting those discoveries inside the wider picture of incretin biology. From there the talk turns to the urgent need for effective therapies in metabolic dysfunction–associated steatohepatitis (MASH), the rationale for GLP-1 receptor agonists in that disease, the key benefits and concerns seen in clinical use, and the NIH studies now under way to pin down mechanisms of action and predictors of response.
Between them, the speakers hope the audience comes away with a clear picture of how fundamental peptide biochemistry produced one of the most consequential therapeutic classes in modern medicine - and which mechanistic and clinical questions are still open.
Svetlana Mojsov <https://www.rockefeller.edu/our-scientists/research-affiliates/1055-svetlana-mojsov/> holds the Lulu Chow Wang and Robin Chemers Neustein Research Associate Professorship at The Rockefeller University. With a Breakthrough Prize in Life Sciences (2025) and a Lasker-DeBakey Clinical Medical Research Award (2024) to her name, Mojsov was central to identifying the biologically active form of GLP-1, GLP-1(7-37), and to showing that it works as an incretin able to stimulate insulin secretion. That work laid critical groundwork for GLP-1-based therapies for type 2 diabetes and obesity.
Yaron Rotman <https://irp.nih.gov/pi/yaron-rotman> is an NIH senior investigator, chief of the Liver & Energy Metabolism Section in the NIDDK Liver Diseases Branch, and an attending hepatologist at the NIH Clinical Center. Mechanistic and translational studies of metabolic dysfunction–associated steatotic liver disease are his focus, drawing on clinical trials, human genetics and experimental models to map the pathways behind hepatic fat accumulation and injury.
With a line-up like that, expect to be dazzled and demystified as always